226 related articles for article (PubMed ID: 34417901)
1. Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.
Nowbar AN; Francis DP; Al-Lamee RK
Cardiovasc Drugs Ther; 2022 Oct; 36(5):1011-1018. PubMed ID: 34417901
[TBL] [Abstract][Full Text] [Related]
2. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
[TBL] [Abstract][Full Text] [Related]
3. Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.
Al-Lamee RK; Shun-Shin MJ; Howard JP; Nowbar AN; Rajkumar C; Thompson D; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik I; Bual N; Cook C; Ahmad Y; Seligman H; Sharp ASP; Gerber R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom S; Davies JE; Francis DP
Circulation; 2019 Dec; 140(24):1971-1980. PubMed ID: 31707827
[TBL] [Abstract][Full Text] [Related]
4. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
Nowbar AN; Rajkumar C; Foley M; Ahmed-Jushuf F; Howard JP; Seligman H; Petraco R; Sen S; Nijjer SS; Shun-Shin MJ; Keeble TR; Sohaib A; Collier D; McVeigh P; Harrell FE; Francis DP; Al-Lamee RK
EuroIntervention; 2022 Apr; 17(18):1490-1497. PubMed ID: 35156616
[TBL] [Abstract][Full Text] [Related]
5. Angina After Percutaneous Coronary Intervention: Patient and Procedural Predictors.
Collison D; Copt S; Mizukami T; Collet C; McLaren R; Didagelos M; Aetesam-Ur-Rahman M; McCartney P; Ford TJ; Lindsay M; Shaukat A; Rocchiccioli P; Brogan R; Watkins S; McEntegart M; Good R; Robertson K; O'Boyle P; Davie A; Khan A; Hood S; Eteiba H; Berry C; Oldroyd KG
Circ Cardiovasc Interv; 2023 Apr; 16(4):e012511. PubMed ID: 36974680
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
[TBL] [Abstract][Full Text] [Related]
7. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.
Simader FA; Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Chotai S; Bual N; Khokhar A; Gohar A; Lampadakis I; Ganesananthan S; Pathimagaraj RH; Nowbar A; Davies JR; Keeble TR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Spratt JC; Williams R; Nijjer SS; Sen S; Curzen N; Sinha M; Howard JP; Cole G; Harrell FE; Francis DP; Shun-Shin MJ; Al-Lamee RK;
J Am Coll Cardiol; 2024 Jul; 84(1):13-24. PubMed ID: 38759906
[TBL] [Abstract][Full Text] [Related]
8. The challenges of a randomised placebo-controlled trial of CTO PCI vs. placebo with optimal medical therapy: The ORBITA-CTO pilot study design and protocol.
Khan S; Fawaz S; Simpson R; Robertson C; Kelly P; Mohdnazri S; Tang K; Cook CM; Gallagher S; O'Kane P; Spratt J; Brilakis ES; Karamasis GV; Al-Lamee R; Keeble TR; Davies JR
Front Cardiovasc Med; 2023; 10():1172763. PubMed ID: 37206100
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
McCreanor V; Nowbar A; Rajkumar C; Barnett AG; Francis D; Graves N; Boden WE; Weintraub WS; Al-Lamee R; Parsonage WA
BMJ Open; 2021 Feb; 11(2):e044054. PubMed ID: 33563623
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
Al-Lamee R; Thompson D; Dehbi HM; Sen S; Tang K; Davies J; Keeble T; Mielewczik M; Kaprielian R; Malik IS; Nijjer SS; Petraco R; Cook C; Ahmad Y; Howard J; Baker C; Sharp A; Gerber R; Talwar S; Assomull R; Mayet J; Wensel R; Collier D; Shun-Shin M; Thom SA; Davies JE; Francis DP;
Lancet; 2018 Jan; 391(10115):31-40. PubMed ID: 29103656
[TBL] [Abstract][Full Text] [Related]
11. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader FA; Chotai S; Pathimagaraj RH; Mohsin M; Salih A; Wang D; Dixit P; Davies JR; Keeble TR; Cosgrove C; Spratt JC; O'Kane PD; De Silva R; Hill JM; Nijjer SS; Sen S; Petraco R; Mikhail GW; Khamis R; Kotecha T; Harrell FE; Kellman P; Francis DP; Howard JP; Cole GD; Shun-Shin MJ; Al-Lamee RK
Lancet; 2024 Apr; 403(10436):1543-1553. PubMed ID: 38604209
[TBL] [Abstract][Full Text] [Related]
12. Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.
Ganesananthan S; Rajkumar CA; Foley M; Thompson D; Nowbar AN; Seligman H; Petraco R; Sen S; Nijjer S; Thom SA; Wensel R; Davies J; Francis D; Shun-Shin M; Howard J; Al-Lamee R
Eur Heart J; 2022 Sep; 43(33):3132-3145. PubMed ID: 35639660
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous Coronary Intervention in Patients Without Acute Myocardial Infarction in China: Results From the China PEACE Prospective Study of Percutaneous Coronary Intervention.
Lu Y; Zhang H; Wang Y; Zhou T; Welsh J; Liu J; Guan W; Li J; Li X; Zheng X; Spertus JA; Masoudi FA; Krumholz HM; Jiang L
JAMA Netw Open; 2018 Dec; 1(8):e185446. PubMed ID: 30646292
[TBL] [Abstract][Full Text] [Related]
14. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
15. Rates of Elective Percutaneous Coronary Intervention in England and Wales: Impact of COURAGE and ORBITA Trials.
Rashid M; Stevens C; Wijeysundera HC; Curzen N; Khoo CW; Mohamed MO; Aktaa S; Wu J; Ludman PF; Mamas MA
J Am Heart Assoc; 2022 Sep; 11(18):e025426. PubMed ID: 36102261
[TBL] [Abstract][Full Text] [Related]
16. Effects of visualization of successful revascularization on chest pain and quality of life in chronic coronary syndrome: study protocol for the multi-center, randomized, controlled PLA-pCi-EBO-pilot-trial.
Wester M; Koll F; Zeman F; Dempfle A; Koller M; Frey N; Maier LS; Sossalla S
Trials; 2020 Oct; 21(1):838. PubMed ID: 33032655
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, randomised, placebo-controlled trial of the coronary sinus Reducer in refractory angina: design and rationale of the ORBITA-COSMIC trial.
Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader F; Pathimagaraj RH; Nijjer S; Sen S; Petraco R; Clesham G; Johnson T; Harrell FE; Kellman P; Francis D; Shun-Shin M; Howard J; Cole GD; Al-Lamee R
EuroIntervention; 2024 Feb; 20(3):e216-e223. PubMed ID: 38214677
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
Ferrari R; Ford I; Fox K; Challeton JP; Correges A; Tendera M; Widimský P; Danchin N;
Lancet; 2020 Sep; 396(10254):830-838. PubMed ID: 32877651
[TBL] [Abstract][Full Text] [Related]
19. Quality of Life After Fractional Flow Reserve-Guided PCI Compared With Coronary Bypass Surgery.
Fearon WF; Zimmermann FM; Ding VY; Zelis JM; Piroth Z; Davidavicius G; Mansour S; Kharbanda R; Östlund-Papadogeorgos N; Oldroyd KG; Wendler O; Reardon MJ; Woo YJ; Yeung AC; Pijls NHJ; De Bruyne B; Desai M; Hlatky MA;
Circulation; 2022 May; 145(22):1655-1662. PubMed ID: 35369704
[TBL] [Abstract][Full Text] [Related]
20. Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(5):1-70. PubMed ID: 23074496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
